spacer
home > pmps > spring 2017 > security breach
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Security Breach

Approximately 40% of all pharmaceutical products available in the US are manufactured outside of the country. It is thought that 80% of the active ingredients in drugs are made and delivered from all over the world, and these must meet the country-specific regulatory requirements of the locations in which they are going to be sold. This highlights the complexity of the industry’s supply chain.

Like many high-value commodities, pharmaceuticals are attractive to criminals – whether they are online hackers or opportunistic individuals who hijack a truck and remove its goods – with no concern whether they are life-saving drugs, prescription medication or lifestyle products.

Negating threats means thoroughly assessing your entire distribution network to determine penetration points. This can include screening vendors to ensure that they have the proper cybersecurity measures in place; scrutinising physical vulnerabilities along the route where goods can be tampered with; and identifying countries and regions with high risks for disruptions to business continuity that can potentially impact your ability to get products from point A to B.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Steve Ward serves as Vice President for the Global Intellectual Property Protection division at Pinkerton, a global provider of corporate risk management services including security consulting, investigations, executive protection, employment screening, protective intelligence and more.
spacer
Steve Ward
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Oxford Genetics licenses SnapFast™ expression vectors to Twist Bioscience

November 16, 2017, Oxford, England and San Francisco, US. – Oxford Genetics, a leader in innovative synthetic biology-based technologies for biologics discovery, development and delivery, announced today a new licensing agreement with Twist Bioscience Corporation, a company enabling customers to succeed through its offering of rapid, high-quality synthetic DNA. Oxford Genetics will supply Twist Bioscience with its SnapFast™ technology platform to provide a broad range of application-specific expression vectors which Twist Bioscience will use to clone synthesized DNA for its diverse customer base.
More info >>

White Papers

8 Ways To Reduce Tablet Manufacturing Costs

Natoli Engineering Company, Inc.

It’s no surprise that in today’s economy, companies are facing budget cuts across the board. In an effort to address these challenges, this list of 8 Ways to Reduce Tablet Manufacturing Costs was compiled.
More info >>

 
Industry Events

5th Biennial Biosimilars & Biobetters Congress 2018

16-17 April 2018, Novotel London West Hotel, Hammersmith, London

Oxford Global are proud to present our highly anticipated 5thBiennial Biosimilars & Biobetters Congress, 16th – 17thApril 2018, London, UK. Over 450 proteins, peptides and biosimilars delegates representing leading biotech companies, global pharmaceutical organisations and internationally renowned academic institutions will enjoy over 20 presentations and case studies focusing on the key areas of the biosimilars industry including market access strategies, clinical development, commercialisation, manufacturing and bio-analytics
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement